Announcements
Neupro patches
Neupro (rotigotine; UCB Pharma) patches should now be refrigerated (2–8C),
following advice from the European Medicines Agency.
The new storage
conditions are intended to reduce occurrence of crystallisation of the
active substance in the patch.
UCB Pharma reports that it has not observed
a change in the pattern of clinically relevant events, including lack
of efficacy, that could be attributed to formation of crystals (which
resemble snowflakes and may cover up to 40 per cent of the patch surface).
UCB
will be introducing refrigerated stock over the next few months; for
a period, beginning late June 2008, the market will only be supplied
with 2mg/24h and 4mg/24h patches.
The company warns that patients should
not
stop using the Neupro patches abruptly and that patients’ existing
stock can be used in the interim. |
The
Pharmaceutical Journal